-
Please ask your patients to participate!26/03/2018
The Cluster Headache Questionnaire (CHQ) is a survey consisting of 144 possible questions, translated in 10 languages,about your patient's experience with Cluster Headache attacks.
Please share this with your patients to help measure the impact cluster headache has on sufferers and their families.
Visit www.clusterheadache.center for more information and see attached document
Survey closes 20 April 2018
-
Request for Proposals for migraine research grants now open21/03/2018
The Migraine Research Foundation (MRF) and the Association of Migraine Disorders (AMD) announce the opening of a joint Request for Proposals for migraine research grants. They are looking for projects that will help sufferers by advancing our ability to understand and treat migraine. As a result, seed money grants are available for transformational projects that will ultimately lead to better treatment and quality of life for sufferers of migraine and migraine disorders
While all proposals relevant to basic or clinical migraine research are welcome, they are particularly interested in translational projects and those related to migraine variants, childhood migraine, and chronic migraine.
Award value: A maximum of $50,000 will be awarded for each grant.
Duration: The expected project duration is one year.
Application deadline: 3 August 2108
For more information see information below or visit http://migraineresearchfoundation.org/for-researchers/2018-mrf-impact-award/
-
IHS Guidelines for preventive treatment of CM now published online in Cephalalgia13/03/2018
The IHS Clinical Trials Committee has updated the 'Guidelines of IHS for controlled trials of preventive treatment of chronic migraine in adults' and this has been published today online in Cephalalgia.
The guidelines can be viewed and downloaded in the Guidelines section
-
Three new members have joined Trainees and Residents group08/03/2018
IHS welcomes three new members to the Trainees and Residents Special Interest Group (T&R SIG):
Sajedeh Eftekhari (Sweden)
Miji Lee (S Korea)
Francesca Puledda (UK)Congratulations and welcome!
-
A list of potential centres for placements is now available02/03/2018
IHS is compiling a list of placement opportunities for Headache Trainee and Short-stay Scholarship applicants. This list to date can be downloaded below and will be included in the Awards section and updated as more centres are confirmed
Applicants are still able to identify centres themselves and contact potential mentors
-
Application now open01/03/2018
The intake for new students to the next Master of Headache Disorders at University of Copenhagen is now opened. The 18 first Masters in Headache Disorders are in the last phase of their program now focusing on their Master thesis and will graduate in June 2018. The program has been very successful due to excellent top ranked international lecturers, our sponsors and the very dedicated and highly motivated students
For more information see below and click HERE to visit the website
-
IHS is looking for host institutions for Headache Trainees and Short-stay Scholars20/02/2018
IHS offers grants and fellowships to young people to further their studies in Headache Medicine.
Two programmes are specifically aimed at young people from developing nations – the Education Committee ‘Headache Trainee Programme’ and the Trainees and Residents SIG ‘Short-stay Scholarship’. The information and application for both these programmes can be found HERE.
We are often asked by young people from these countries, who are not as in touch with the major research and clinical headache centres and headache specialists, for suggestions as to who they can approach to discuss a possible placement, and during the Emerging Leaders session held during IHC 2017 we said IHS would post a list of headache centres and mentors willing to accept fellows on the website.
We would be most grateful for your help with this. If you could host one of these Trainees or Scholars for the short period of time for these programmes (up to 3 months for the Trainee programme and from 4-6 weeks for the Short-stay Scholarship) please let us know. All we will need from you is:- Institution name
- Mentor name
- Contact email address
- Type of placement: Clinical; Clinical Research; Basic Research; Combination (please
Please send to Carol Taylor or contact Carol if you would like any further information
-
The final version of the eagerly awaited ICHD-3 is now available online on the Cephalalgia website25/01/2018
The final version of the eagerly awaited International Classification of Headache Disorders, 3rd edition (ICHD-3) ( Cephalalgia 2018, vol 28, issue 1) is now available online on the Cephalalgia website and in the Guidelines section of the IHS website.
The ICHD-3 is freely available.
If you would like a print copy, these can be purchased from the Publisher. Please email subscriptions@sagepub.co.uk and quote ‘volume 38 issue 1 ICHD-3'
-
IHC 2017 posters are now uploaded in the Poster Library31/10/2017
A selection of posters presented at IHC 2017, Vancouver, are now freely available in the IHS website Poster Library which can be found in the Learning Centre
If you presented a poster at IHC 2017 and would like it to be included please send as a pdf to Carol Taylor
-
The late-breaking abstracts are now included in the Cephalalgia IHC abstract supplement25/10/2017
The late-breaking abstracts submitted to IHC 2017, Vancouver, are now included in the Cephalalgia IHC abstract supplement. Click HERE to access
RELATED WEBSITE: Cephalalgia 2017 suppl 1 -
A silhouette open-access title to Cephalalgia has been launched and is now open for submissions25/10/2017
New for January 2018!
Cephalalgia Reports – A fully Open Access Journal from the International Headache Society
Published on behalf of the International Headache Society, Cephalalgia Reports is a peer reviewed, open access publication providing an international forum for original research papers, review articles, clinical perspectives, case reports, technical reports and short communications.
It actively encourages high quality papers in the following areas:
- Emerging observations with translational potential not yet realized
- Reports limited to regional relevance which may validate and add to existing studies
- RCTs with negative outcomes
- Confirmatory studies
- Technical reports
- Articles with a more clinical emphasis
- Pilot trials which may stimulate therapeutic innovation
- Scientifically rigorous pathophysiological and pharmacological studies
All articles are freely available online immediately upon publication.
All articles are rigorously peer-reviewed, and brought to publication as rapidly as possible.
For questions about submitting papers, or the suitability of your manuscript, please contact the Managing Editor, Wendy Krank: editorial.cephalalgia@gmail.com
Cephalalgia Reports
- Has the same internationally respected editorial team and rigorous peer review as Cephalalgia
- Operates under an open access publishing model, where an article processing charge (APC) enables the article to be free to access. Content published is available for anyone, anywhere to read, offering truly global dissemination. This includes those in developing countries and others who may not otherwise have access to the content, fulfilling one of the IHS's primary objectives to advance headache science, education, and management, and promote headache awareness worldwide
- Published articles are made available with no subscription pay-walls; the full-text of articles are freely available online immediately upon publication
- Cephalalgia Reports publishes under a Creative Commons Attribution Non-Commercial license (CC-BY-NC) which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. Though CC-BY-NC will be the default licence, Cephalalgia Reports will be able to accommodate authors who are required to publish under a CC-BY licence funder mandate, which allows use the work for commercial purposes
- The journal publishes in full colour with no colour of page charges
- Cephalalgia Reports uses a ScholarOne online manuscript and peer-review system; all papers are run through the iThenticate plagiarism software, then reviewed by at least two independent reviewers
- Cephalalgia Reports has the same high-quality copy-editing, typesetting and online publication enjoyed by Cephalalgia
- Article Processing Charges
In an Open Access journal, all papers are free to read as the cost of publication is covered by the author/funders. APCs for Cephalalgia Reports are listed below.
Price Category
APC
Full price
$1,500
IHS members
$1,000
Junior IHS members and journal editorial board members
$750
Waivers: for authors from developing countries under the RESEARCH4LIFE scheme
$0
To submit click HERE
News Archive
-
Congratulations to IHC prize winners
31/10/2017
IHS congratulates IHC 2017 Trainees Excellence Tournament and poster prize winners
Trainees Excellence Tournament
Clinical Presentation
Julia Hebestreit - Topiramate inhibits thalamic activity during trigeminal pain in humans
Scientific Presentation
Inge Loonen - Functional characteristics of non-invasively optogenetically induced CSD in FHM1 mutant mice
Poster prizes
T&R SIG choice
Altered brainstem anatomy in migraine
Noemi Meylakh, Flavia Di Pietro, Kasia Marciszewski, Vaughan Macefield, Luke Henderson, Paul MaceyPeople's choice
Infusion of calcitonin gene-related peptide provokes cluster headache attacks
Anne Luise Vollesen, Agneta Snoer, Rasmus Paulin Beske, Song Guo, Rigmor Højland Jensen, Messoud Ashina, Jan Hoffmann -
Jes Olesen recognition for ICHD leadership
19/09/2017
IHS recognises the enormous contribution of Professor Jes Olesen in leading the development of ICHD. ICHD has provided the basis for advances in the clinical and biological understanding of headache disorders and continues to facilitate the progress in treatment.
-
Chris Diener receives IHS Special Recognition Award
18/09/2017
Professor Hans-Christoph Diener is seen receiving his award from IHS President, Professor David Dodick during the IHC 2017 Opening Ceremony on 7 September 2017
Photo: JON BENJAMIN PHOTOGRAPHY
-
IHC 2017 Presidential Symposium
15/09/2017
VANCOUVER, B.C., SEPTEMBER 7-10, 2017 — The theme of the 2017 Congress of the International Headache Society, “New Horizons in Headache,” nods to both the location of the conference in Vancouver, B.C., and to the event’s focus on the new frontier of headache medicine.
“This unprecedented event in headache medicine marks the turning point for a group of diseases that have endured a severe lack of understanding, damaging stigma, historic underfunding for research, and a painfully slow pace of treatment advances,” said Dr. David Dodick, President of the International Headache Society and Co-Chair of the Congress, in his welcoming remarks Sept. 7.
The Presidential Symposium, kickstarting the 2017 Congress of the International Headache Society, follows the first-ever Global Patient Advocacy Symposium, a one-day intensive connecting leaders in headache medicine with public health organizations, patient advocacy groups and other interdisciplinary allies to establish mutual international patient support goals.
Awards and Recognitions
The ceremony opened by honoring the accomplished life of Ninan Mathew (1937-2015), founder of the Houston Headache Clinic and former president of the International Headache Society. Prof. Jes Olesen was the recipient of the IHS Lifetime Achievement Award for his outstanding accomplishments with the Danish Headache Center, which are exemplary in the field. In addition, Dr. Hans-Christoph Diener received the IHS Special Recognition Award for his integrity, ethics, and professionalism, all of which have earned him remarkable respect amongst colleagues around the world.
Accomplishments
Since the last Congress in 2015, the organization has made several key developments, reaching critical goals that include to sustain and grow global education, build a global network of researchers, and to mentor and develop future leaders, including the development of a women’s leadership program. In addition, the IHS just surpassed the largest membership base in the history of the organization. At the Symposium, Dodick announced that IHS has developed and launched a full, open access companion journal to Cephalalgia, called Cephalalgia Reports. The new journal will include original research papers, review articles, clinical perspectives, case reports, CME articles, technical reports and more.
New Horizons
Called the most exciting field in neurology, and the most groundbreaking moment in headache medicine, new advancements are indeed on the horizon. Highlighting four key breakthrough areas in the field, International Headache Congress began with a Presidential Symposium including presentations to address the new horizons in headache imaging, translational research, genetics and novel treatment targets, presented by Drs. Todd Schwedt, Frank Porecca, Michel Ferrari and Peter Goadsby, respectively.
Global Patient Advocacy Call to Action
In an effort to build an emphasis on patient-centric care, the 2017 Congress was preceded by the first ever Global Patient Advocacy Summit. To continue the momentum, a motion to globalize migraine patient advocacy has been made through the forming of the Global Patient Advocacy Coalition (GPAC). Objectives of the GPAC include country-specific research surrounding the formation of a global migraine approach to advocacy, resources to develop local outreach, evaluation of local initiatives, refinement of tactics and needs assessment.
The Congress brings together hundreds of leaders from the International Headache Society’s membership for four days of lectures, networking, peer education and expert panels focused on the world of headache science, education and management at the unique Vancouver Convention Centre. IHC2017 will include plenary sessions, an extensive poster display and in-depth scientific presentations showcasing basic and clinical research that that promises an exciting future for headache medicine.
“We have the collective brain trust, commitment, and influence in this room today to change all of that for the hundreds of millions who suffer with disabling headache around the globe by building awareness, raising support, delivering education, and improving access to care,” says Dr. Dodick.
-
Cephalalgia Award Lecture presented at IHC
09/09/2017
Congratuations to Thomas Linman and colleagues who have received the Cephalalgia Award Lecture for their article 'Circulating endothelial microparticles in female migraineurs with aura'. Cephalalgia 2015;35:88-94
His presentation will take place at the IHC 2017 this evening.
-
IHS awards Special Recognition and Life Membership
09/09/2017
Congratulations to Dr Hans-Christoph Diener, past IHS President, on receiving the IHS Special Recognition Award in 2017.
Congratuations also to Dr Alan Rapoport for receiving his Life Membership certificate as he transitions off the Board having served his term as Immediate Past-President.
-
Welcome to the new IHS Trustees
08/09/2017
Following the IHS Annual General Meeting Dr Lars Edvinsson steps into the role of President.
We welcome Dr Messoud Ashina as IHS President-elect and Dr Mario Peres, Dr Patricia Pozo-Rosich and Dr Todd Schwedt as elected Trustees.
Many thanks to the Trustees who are leaving the Board for their tireless efforts on behalf of the society:
Alan Rapoport - Past-President
Rami Burstein
Fayyaz Ahmed
Werner Becker
Mamoru Shibata
Alessandro Zagami -
First-Ever Global Patient Advocacy Summit
06/09/2017
SEPTEMBER 6, 2017, 8:00 AM PDT: VANCOUVER, B.C. — For the first time in the history of headache medicine, the top representatives from 49 International Headache Society member groups will gather for a one-day summit to identify the most essential global goals for the field with an emphasis on patient support. The Global Patient Advocacy Summit (GPAS), held on Sept. 6, 2017, kicks off the four-day, 18th Congress of the International Headache Society, and represents a groundbreaking interdisciplinary effort between doctors, researchers, government agencies and patient advocates to design a blueprint to close gaps in headache diagnosis, research and treatment.
“Individuals living with migraine bear multiple burdens. Not only is their disease potentially debilitating, it’s also invisible, misunderstood and deprived of the necessary investment in research that’s proportional to its devastating scope,” said Dr. David Dodick, President of the International Headache Society and Co-Chair of the Congress. “Migraine is identified by the World Health Organization as the third most disabling medical illness on the planet. The Global Patient Advocacy Summit represents a focused, organic partnership between doctors, patients and public health organizations to rectify that inequity, and make progress in the field of headache medicine."
Through a series of panels and interorganizational sessio
ns, the goal of the one-day summit is to identify opportunities for patient advocacy around the globe, and the avenues by which leading professional medical societies, patient advocacy groups, and industry leaders can help facilitate and support these efforts. “There is a staggering 37 million people living with migraine in the United States alone. Many of those people have never had their symptoms taken seriously or even addressed by a headache specialist,” said Meghan Buzby, Executive Director of the American Migraine Foundation, a partner organization presenting at the summit. “The more resources we can dedicate to education and driving public awareness, the more effective we will be at giving millions of people the tools they desperately need to advocate for their health and overall well-being.”
In addition to patient advocacy, one of the key meeting initiatives is to identify mechanisms to expand and improve patient access to healthcare services and treatment. New research has led to the development of groundbreaking therapies that could change the lives of millions of migraine patients around the world. Still, even in developed countries, migraine and headache research lacks access to publicly available research dollars. The massive and disproportionate lack of funding, relative to the disease's prevalence and its overall economic burden, has resulted in a glacial pace of treatment advances—a problem the summit attendees pledge to overcome in time.
The Global Patient Advocacy Summit represents a robust commitment to headache medicine and a uniform approach to a patient-centric offensive against the disabling disease. Elevating the profile of migraine, educating patients on advocacy opportunities, strategizing solutions to overcome barriers to treatment and organizing awareness campaigns for employers, governments and the general public are key agenda items the summit will address.
At the conclusion of the one-day event, participants will collaboratively generate a white paper and a strategic blueprint for migraine patient advocacy that will be published in Cephalalgia, the International Headache Society’s medical journal.
Participating organizations include the World Health Organization, the U.S. Food and Drug Administration, various nonprofit organization
s such as the American Migraine Foundation, American Academy of Neurology and other leading patient advocacy groups and national medical agencies from around the globe. About the International Headache Society:
The International Headache Society is the world’s leading membership organization for all whose professional commitment, whatever their discipline, is to helping people whose lives are affected by headache. As a charity, the purpose of IHS is to advance headache science, education, and management, and promote headache awareness worldwide. Activities include publication of Cephalalgia, the biennial International Headache Congress, developing guidelines, the international headache classification, educating the next generation of headache specialists worldwide, online education materials and offering grants and fellowships to young physicians worldwide. For more information about the IHS, visit their website: http://www.ihs-headac
he.org About Migraine/Headache:
Migraine is the third most prevalent and sixth most disabling medical illness in the world. Despite the more than 1 billion people affected by migraine around the globe, it is vastly underrecognized and undertreated, and there remains tremendous disparity in patient access to education, healthcare services, and drug, device, and non-pharmacological treatments. Individuals who experience migraine have symptoms that include nausea, sensitivity to light and/or odors, skin sensitivity, fatigue, mood change, dizziness, difficulty concentrating, neck pain and changes in vision, including seeing spots, stars, lines, flashing lights and zigzag lines. The risk of other serious diseases is significantly higher in those with migraine, including stroke, epilepsy, depression, anxiety and chronic pain. Despite this, only one of every three people talk with a doctor about their migraine attacks and of those, only half get the right diagnosis. There is also a massive shortage of specialists focusing on migraine, with one specialist for every 65,000 individuals living with migraine, which worsens the problem.
Media Inquiries:
Lizzie Tufano
(708) 705-0822
lizzie@yakketyyak.com
318 W. Adams Ste 1607, Chicago, IL 60606 -
MRF announces 2015 award recipients
18/12/2015
The Migraine Research Foundation is pleased to announce the recipients of the research grants awarded for 2015. The grants will help research into new migraine biomarkers, identifying new treatments from traditional Chinese medicine, studying New Daily Persistent Headache, and more. For information on the awardees see HERE.
-
New Editor-in-Chief for Cephalalgia
18/09/2015
IHS is very pleased to announce that Arne May will succeed David Dodick as Editor-in-Chief of Cephalalgia from January 2016.
Arne has served on the IHS Board of Trustees since June 2013, and as an Associate Editor of Cephalalgia since March 2009. He is currently head of one of the largest headache outpatient clinics in Germany, based at the University Clinic in Hamburg (UKE). His scientific interest in headache is long-standing, and he has published papers and book chapters on genetics, epidemiology, physiology and pathophysiology of the trigeminovascular system, headache classification and phenotype, as well as functional imaging.
Arne said "This is a huge opportunity and I am very honoured to be appointed. All my vigour will be to keep Cephalalgia where it has so successfully been led by David Dodick and former Editors: the best journal to publish the best headache science available".
-
IHS Visiting Professors in Bulgaria and Estonia
12/08/2015
Alan Rapoport and Nina Latysheva attended the 14th Bulgarian National Congress in Varna, Bulgaria, in May as IHS Visiting Professors. Read the meeting report here.
Messoud Ashina and Alan Rapoport presented at the 2015 Estonian Headache Society annual meeting - Mark Braschinsky reports.
Slide presentations from the Estonian meeting, and also the Moroccan and Azerbaijan Visiting Professor meetings, are available in the Learning Centre/Visiting Professors.
- 5th ARCH meeting report 28/07/2015
- Report on 1st Pan-African meeting 28/07/2015
-
Visiting Professor Reports - Azerbaijan, Morocco
28/07/2015
The IHS Visiting Professor initiative sends headache specialists as representatives of IHS to attend regional meetings, or teach at a headache centre, in countries that might need or want increased headache education and motivation but where without financial support attendance of an international specialist would not be possible.
We report on two recent Visiting Professor projects in Azerbaijan and Morocco.
-
ICHD-3-beta Portuguese translation
28/07/2014
A Portuguese translation of the ICHD-3-beta is now available.
This work has been completed by a team of Portuguese headache specialists, including José Pereira Monteiro (Coordinator), José Rocha Barros, Paula Esperança, Gabriela Fernandes, Helena Gens, Raquel Gil Gouveia, Isabel Luzeiro, Jorge Machado, Isabel Pavão Martins, Fernando Matias, Maria Manuela Palmeira, Elsa Parreira, Carlos Fontes Ribeiro, Alfredo Sá and Lívia Sousa.
The translation will be published in the official Journal of the Portuguese Neurological Society (Sinapse) to enable dissemination of this highly relevant information for daily clinical practice among our Portuguese-speaking colleagues, over the world.
The translation was sponsored by the Portuguese Headache Society and the Portuguese Neurological Society.
-
'Headache and Pain' - book published
10/03/2014
Headache and other types of pain have some common characteristics concerning pain generation and chronicity. But some distinct pathophysiological processes are unique to the headache. This book explores pain mechanisms, diagnosis, and management of headache and other chronic pain through sessions of a joint symposium of IASP and the International Headache Society. This book, edited by Ralf Baron (IASP) and Arne May (IHS), represents the current state of scientific discussions of the respective fields in both pain areas.
See the IASP website for more information
- ICHD-3-beta Spanish translation 17/02/2014
-
ICHD-3-beta slide kit now available
17/02/2014
- Additional ICHD-3-beta slides now available 09/09/2013
-
ICHD-3-beta slides now available
06/09/2013
-
Cephalalgia App released
20/06/2013
The Cephalalgia App is now available for download through the iTunes store.
Simply click here to see the Cephalalgia app in iTunes.
The App will be freely available until the end of August, when it will become an IHS membership benefit.
- ICHD-3 beta now published 17/06/2013
- Dr Marcia Wilkinson, one of the first Editors of Cephalalgia, has died aged 93 05/02/2013